The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II trial of sunitinib as adjuvant therapy after stereotactic radiosurgery (SRS) in patients with 1-3 newly diagnosed brain metastases.
David M. Peereboom
Research Funding - Pfizer
Samuel T. Chao
No relevant relationships to disclose
John H. Suh
No relevant relationships to disclose
Ding Wang
No relevant relationships to disclose
Tom Mikkelsen
No relevant relationships to disclose
Cathy J. Brewer
No relevant relationships to disclose
Kathy N. Smolenski
No relevant relationships to disclose
Michael W. Parsons
No relevant relationships to disclose
Paul Elson
No relevant relationships to disclose
Lilyana Angelov
No relevant relationships to disclose
Gene H. Barnett
No relevant relationships to disclose
Michael A. Vogelbaum
No relevant relationships to disclose
Robert J. Weil
No relevant relationships to disclose